Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia

Igor Elman, David Rott, Alan I. Green, Daniel D. Langleben, Scott E. Lukas, David S. Goldstein, Alan Breier

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Rationale: Several lines of evidence suggest that the pathophysiology of schizophrenia may be associated with altered noradrenergic and glucoregulatory function. Objective: The aim of this study was to investigate these alterations during a perturbed homeostatic state. Methods: Fifteen patients with schizophrenia and 13 healthy individuals were given a glucose deprivation challenge through administration of pharmacological doses of 2-deoxyglucose (2DG; 40 mg/kg), and their plasma was assayed over the next 60 min for concentrations of norepinephrine (NE), the intraneuronal NE metabolite dihydroxyphenylglycol (DHPG), epinephrine and glucose. Results: 2DG induced significant increases in plasma NE, epinephrine and glucose levels in both groups with significantly greater NE and glucose increments in patients than in controls. For DHPG, 2DG produced increases in patients and decreases in the control subjects. NE responses correlated positively and significantly with the DHPG and glucose responses in schizophrenics, but not in controls. Conclusions: These findings suggest that patients with schizophrenia have exaggerated NE and glucose responses to an acute metabolic perturbation.

Original languageEnglish (US)
Pages (from-to)369-375
Number of pages7
JournalPsychopharmacology
Volume176
Issue number3-4
DOIs
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

Deoxyglucose
Catecholamines
Schizophrenia
Norepinephrine
Pharmacology
Glucose
Epinephrine

Keywords

  • 2-Deoxyglucose
  • Dihydroxyphenylglycol
  • Epinephrine
  • Glucoprivation
  • Glucose
  • Norepinephrine
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia. / Elman, Igor; Rott, David; Green, Alan I.; Langleben, Daniel D.; Lukas, Scott E.; Goldstein, David S.; Breier, Alan.

In: Psychopharmacology, Vol. 176, No. 3-4, 11.2004, p. 369-375.

Research output: Contribution to journalArticle

Elman, Igor ; Rott, David ; Green, Alan I. ; Langleben, Daniel D. ; Lukas, Scott E. ; Goldstein, David S. ; Breier, Alan. / Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia. In: Psychopharmacology. 2004 ; Vol. 176, No. 3-4. pp. 369-375.
@article{c0cb87cef5dc483d87071c517bb27046,
title = "Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia",
abstract = "Rationale: Several lines of evidence suggest that the pathophysiology of schizophrenia may be associated with altered noradrenergic and glucoregulatory function. Objective: The aim of this study was to investigate these alterations during a perturbed homeostatic state. Methods: Fifteen patients with schizophrenia and 13 healthy individuals were given a glucose deprivation challenge through administration of pharmacological doses of 2-deoxyglucose (2DG; 40 mg/kg), and their plasma was assayed over the next 60 min for concentrations of norepinephrine (NE), the intraneuronal NE metabolite dihydroxyphenylglycol (DHPG), epinephrine and glucose. Results: 2DG induced significant increases in plasma NE, epinephrine and glucose levels in both groups with significantly greater NE and glucose increments in patients than in controls. For DHPG, 2DG produced increases in patients and decreases in the control subjects. NE responses correlated positively and significantly with the DHPG and glucose responses in schizophrenics, but not in controls. Conclusions: These findings suggest that patients with schizophrenia have exaggerated NE and glucose responses to an acute metabolic perturbation.",
keywords = "2-Deoxyglucose, Dihydroxyphenylglycol, Epinephrine, Glucoprivation, Glucose, Norepinephrine, Schizophrenia",
author = "Igor Elman and David Rott and Green, {Alan I.} and Langleben, {Daniel D.} and Lukas, {Scott E.} and Goldstein, {David S.} and Alan Breier",
year = "2004",
month = "11",
doi = "10.1007/s00213-004-1890-y",
language = "English (US)",
volume = "176",
pages = "369--375",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3-4",

}

TY - JOUR

T1 - Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia

AU - Elman, Igor

AU - Rott, David

AU - Green, Alan I.

AU - Langleben, Daniel D.

AU - Lukas, Scott E.

AU - Goldstein, David S.

AU - Breier, Alan

PY - 2004/11

Y1 - 2004/11

N2 - Rationale: Several lines of evidence suggest that the pathophysiology of schizophrenia may be associated with altered noradrenergic and glucoregulatory function. Objective: The aim of this study was to investigate these alterations during a perturbed homeostatic state. Methods: Fifteen patients with schizophrenia and 13 healthy individuals were given a glucose deprivation challenge through administration of pharmacological doses of 2-deoxyglucose (2DG; 40 mg/kg), and their plasma was assayed over the next 60 min for concentrations of norepinephrine (NE), the intraneuronal NE metabolite dihydroxyphenylglycol (DHPG), epinephrine and glucose. Results: 2DG induced significant increases in plasma NE, epinephrine and glucose levels in both groups with significantly greater NE and glucose increments in patients than in controls. For DHPG, 2DG produced increases in patients and decreases in the control subjects. NE responses correlated positively and significantly with the DHPG and glucose responses in schizophrenics, but not in controls. Conclusions: These findings suggest that patients with schizophrenia have exaggerated NE and glucose responses to an acute metabolic perturbation.

AB - Rationale: Several lines of evidence suggest that the pathophysiology of schizophrenia may be associated with altered noradrenergic and glucoregulatory function. Objective: The aim of this study was to investigate these alterations during a perturbed homeostatic state. Methods: Fifteen patients with schizophrenia and 13 healthy individuals were given a glucose deprivation challenge through administration of pharmacological doses of 2-deoxyglucose (2DG; 40 mg/kg), and their plasma was assayed over the next 60 min for concentrations of norepinephrine (NE), the intraneuronal NE metabolite dihydroxyphenylglycol (DHPG), epinephrine and glucose. Results: 2DG induced significant increases in plasma NE, epinephrine and glucose levels in both groups with significantly greater NE and glucose increments in patients than in controls. For DHPG, 2DG produced increases in patients and decreases in the control subjects. NE responses correlated positively and significantly with the DHPG and glucose responses in schizophrenics, but not in controls. Conclusions: These findings suggest that patients with schizophrenia have exaggerated NE and glucose responses to an acute metabolic perturbation.

KW - 2-Deoxyglucose

KW - Dihydroxyphenylglycol

KW - Epinephrine

KW - Glucoprivation

KW - Glucose

KW - Norepinephrine

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=10944253021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10944253021&partnerID=8YFLogxK

U2 - 10.1007/s00213-004-1890-y

DO - 10.1007/s00213-004-1890-y

M3 - Article

C2 - 15179540

AN - SCOPUS:10944253021

VL - 176

SP - 369

EP - 375

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3-4

ER -